Leukaemias in children and adolescents. From symptoms to diagnosis;Leukämien bei kindern und jugendlichen. Vom symptom zur diagnose

Monatsschrift fur Kinderheilkunde

Volumn 151, Issue 2, 2003, Pages 131-137

  Gobel U ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Adolescents; Children; Leukaemia; Symptoms

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYTOSTATIC AGENT; MONOCLONAL ANTIBODY; PREDNISONE; VINCRISTINE;

ADOLESCENT; ARTICLE; BONE MARROW BIOPSY; BONE MARROW DEPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CLINICAL FEATURE; CYTOGENETICS; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; FLUORESCENCE ACTIVATED CELL SORTING; HEMATOPOIETIC SYSTEM; HIGH RISK PATIENT; HUMAN; IMMUNOPHENOTYPING; PATHOPHYSIOLOGY; PROGNOSIS; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0037937405     PISSN: 00269298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00112-002-0653-2     Document Type: Article

References (13)

1. Dirksen U, Hattenhorst U,Schneider P et al. (1998) Defective expression of GM-CSF/IL3/IL5 receptor common β-chain in children with acute myeloid leukemia associated with failure. Blood 92: 1097-1103
2. Dongen JJ van, Seriu T, Panzer-Grumayer ER et al. (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352: 1731-1738
3. Felix CA (1999) Evidence of early start for common acute lymphoblastic leukaemia. Lancet 354: 1486-1487
4. Janka-Schaub GE, Harms DO, Boer ML den,Veerman AJ, Pieters R (1999) In vitro drug resistance as independent prognostic factor in the study COALL-05-92. Treatment of childhood acute lymphoblastic leukaemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97. Klin Pädiatr 211: 233-238
5. Fine HA (2002) Primary central nervous system Lympho:Time to ask the question. J Clin Oncol 20: 4615-4617
6. Kaatsch P, Spix C, Michaelis J (2001) Kinderkrebsregister Jahresbericht 2000. Lindner, Mainz
7. Kaspers GJL, Zwaan ChM, Veerman AJP et al. (1999) Cellular drug resistance in acute myeloid leukemia: literature review and preliminary analysis of an ongoing collaborative study. Klin Pädiatr 211: 239-244
8. Körholz D, Göbel U (1995) Lymphknotenvergrößerungen im Kindesalter. Monatsschr Kinderheilkd 143: 1023-1033
9. Lansdorp PM (1997) Self-renewal ofstem cells. Biol Blood Marrow Transplant 3: 171-178
10. McNeil DE, Coté TR, Clegg L, Mauer A (2002) SEER update of incidence and trends in pediatric malignancies: acute lymphoblastic leukemia. Med Pediatr Oncol 39: 554-557
11. Schilling FH, Spix C, Berthold F et al. (2002) Neuroblastoma screening at one year of age. N Engl J Med 346: 1047-1053
12. Schrappe M, Creutzig U (2001) Akute lymphoblastische (ALL) und akute myeloische (AML) Leukämie. In: Creutzig U, Henze G (Hrsg) Leitlinien für die Diagnostik und Therapie in der Pädiatrischen Onkologie, 2.Aufl. S 105-120
13. Zur Stadt U, Harms DO, Schlüter S et al. (2001) Synopsis MRD at the end of induction therapy in childhood acute lymphoblastic leukemia: outcome prediction strongly depends on the therapeutic regimen. Leukemia 15: 283-285